The First Migraine Breakthrough Was Not the Finish Line

Vedana Therapeutics is building long-acting antibody medicines that go beyond CGRP, targeting additional migraine biology to help more patients gain reliable control over a disease that can dictate everyday life.

CGRP-targeted medicines changed migraine care by giving physicians treatments designed around migraine biology itself, rather than drugs borrowed from other conditions. For many patients, that shift has been meaningful. But many others still do not achieve adequate control, so the question is how much further that precision can go.

Vedana Therapeutics, a Canaan portfolio company founded by Anurag Agarwal and Leon Garcia, is built around that next question. The company is developing long-acting antibody medicines aimed at PACAP, another signaling molecule involved in migraine, as well as a program designed to target PACAP and CGRP together. For Canaan and our partner Julie Grant, Vedana reflects a lesson from the first wave of migraine innovation: the first pathway that works is not necessarily the last pathway that matters.

For a long time, migraine prevention relied heavily on medicines developed for other conditions. Then CGRP changed the field. Researchers showed that this signaling protein was deeply involved in migraine attacks, and a new class of targeted therapies followed.

That success also created a tempting assumption: once the dominant pathway had been found, the rest was mostly a matter of improving the same approach.

Migraine has not behaved that simply. Patients can experience very different patterns of pain, nausea, light sensitivity, fatigue, and other symptoms, and roughly two-thirds of patients on CGRP therapies still do not achieve adequate disease control. The old assumption Vedana is challenging is not that CGRP was wrong. It is that CGRP was the whole answer.

PACAP, short for pituitary adenylate cyclase-activating polypeptide, is another signaling molecule tied to migraine. In plain English, it appears able to help trigger migraine through biology that is at least partly distinct from CGRP.

Earlier efforts to block one of PACAP's receptors did not show the hoped-for benefit, leaving real uncertainty around the target. More recent clinical data from antibodies that bind PACAP itself have strengthened the case that the pathway can be drugged.

That creates the opening Vedana is entering. The science is no longer purely theoretical, but the product question is still open. If PACAP is a meaningful second pathway, what is the right antibody? Could targeting PACAP and CGRP together help people who remain poorly controlled on a single pathway?

Vedana's public pipeline starts with VDN-0100, an anti-PACAP monoclonal antibody. Its second program, VDN-0200, is a bispecific antibody designed to target PACAP and CGRP at the same time. Both are being developed as long-acting medicines intended for subcutaneous dosing, with first-in-human studies currently planned for 2027.

One program asks whether blocking PACAP can help patients who need an option beyond CGRP. The other asks whether, for some patients, migraine may be better controlled by addressing two clinically important pathways together.

What makes Vedana different is not simply a newer target. The company is applying lessons from the first generation of migraine biologics to potency, duration, administration, patient selection, and combination biology from the beginning. Those choices can determine whether promising biology becomes a medicine people can actually use.

Vedana was assembled differently from many early biotech companies. It did not begin with one molecule and then build a team around it. It began with people who had already helped discover and develop medicines that defined modern migraine treatment.

Leon Garcia and members of the discovery team worked on both Vyepti and the anti-PACAP antibody bocunebart at Alder. Other leaders around Vedana bring experience from AJOVY and Aimovig. Anurag Agarwal's founding insight was to assemble that knowledge around the next biological opportunity in migraine.

That history is central to what Canaan saw. Julie has described Vedana as an expert-team thesis rather than a molecule thesis. Canaan had already seen through its investment in Labrys, whose lead program ultimately became AJOVY after Teva acquired the company, how much hard-won knowledge matters in migraine. With Vedana, the conviction was that the team itself was an asset: people who knew where programs tend to fail, what patients and physicians need, and how to turn promising biology into a development plan.

Migraine is easy to underestimate because much of its burden is invisible. The hardest part is not only the hours of pain. It is the uncertainty around them.

A person with frequent migraine may plan work, childcare, travel, or family time around the possibility that tomorrow becomes unusable. That unpredictability can shrink a life well beyond the hours of an attack.

This is why better prevention matters. The goal is not simply fewer migraine days on a chart. It is more days that can be counted on.

The question Vedana is asking is not simply whether PACAP can become another migraine target. It is whether the next generation of migraine medicine can move from one successful pathway toward a more complete understanding of a disease that does not behave the same way in every patient.

If Vedana succeeds, the significance will not be that biotech found another molecule to block. It will be that more people living with migraine may be able to make plans without building an escape route into every one of them. That is the future Vedana points toward, and the reason this next chapter in migraine treatment matters.